Related Experiment Video
Updated: May 10, 2026
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Development of a Multiple-Epitope-Based Vaccine for Hepatitis C Virus Genotypes 1a and 1b: an in-silico reverse
Enakshi Das1, Mahesh Samantaray1, Kajal Abrol1
1Department of Bioinformatics, Pondicherry University, Kalapet, Puducherry India.
Insights
This study developed a novel Hepatitis C virus (HCV) vaccine using immunoinformatics. The designed multi-epitope vaccine showed promising stability and potential for prophylactic use against HCV variants.
Area of Science:
- Virology
- Immunology
- Vaccine Development
- Bioinformatics
Background:
- Hepatitis C virus (HCV) causes persistent inflammation and is a global health challenge.
- Direct Acting Antivirals have improved treatment, but no effective HCV vaccine currently exists.
- HCV's genetic diversity and complex immune response hinder vaccine development.
Purpose of the Study:
- To design a multi-epitope-based vaccine against the Hepatitis C virus polyprotein using immunoinformatics.
- To evaluate the vaccine construct's properties, including antigenicity, toxicity, and allergenicity.
- To assess the vaccine's binding affinity and stability with human Toll-Like Receptors (TLR3 and TLR8).
Main Methods:
- Utilized immunoinformatics methods to design a multi-epitope vaccine.
- Extracted T-cell epitopes from HCV genotypes 1a and 1b polyprotein.
- Performed molecular dynamics (MD) simulations and immunological simulations to validate vaccine stability and receptor interactions.
Main Results:
- The designed vaccine construct was highly antigenic, non-toxic, and non-allergenic.
- Demonstrated effective binding with human TLR3 and TLR8.
- MD and immunological simulations confirmed the vaccine construct's stability over a 365-day timeline.
Conclusions:
- The in-silico developed multi-epitope vaccine shows potential as a prophylactic measure against HCV variants.
- Further in vivo and in vitro studies are warranted to explore its efficacy.
- This research contributes to the development of safer and more efficient vaccines for infectious diseases.
Abstract:
The Hepatitis C virus (HCV) is a blood-transmitted virus responsible for persistent inflammation, presenting a substantial worldwide health challenge. HCV, characterized by a positive-stranded ribonucleic acid genome, possesses an intricate genetic makeup encoding both structural and non-structural proteins, crucial for sustaining its life cycle. The Direct Acting Antivirals have revolutionized the treatment landscape of HCV promoting higher Sustained Virological Response rates. Despite significant advancements in treatment, no vaccines are currently available against HCV. The development of effective HCV vaccines becomes challenging as the genetic diversity of HCV virus and its complex nature of the immune response required for protection. In this work, the immunoinformatics methods were utilized to develop a multiple-epitope-based vaccine towards an effective treatment against the viral HCV polyprotein. The vaccine was constructed by T-cell epitopes extracted from the viral polyprotein of HCV genotypes 1a and 1b. The vaccine was highly antigenic, non-toxic, and non-allergenic. Effective binding of the designed vaccine construct was studied by forming complexes with the human immune Toll-Like Receptors; TLR3 and TLR8. The MD simulation of these receptor-vaccine complexes were performed for 50ns and the immunological simulation of modeled vaccine in presence of receptors for 365 days timeline validated the stability of the constructed vaccine. The in-silico vaccine construct developed from this work might be beneficial as prophylactic measures against the HCV variants, if explored further in in vivo and in vitro methods. Consequently, this research outcome is presumed to have implications in the development of safer and more efficient vaccines for lethal diseases.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s40203-024-00275-4.
